News & Events

StageBio Presents at 2024 SOT Annual Meeting & Expo

The StageBio team is looking forward to attending the 63nd Annual SOT Annual Meeting & Expo on March 10-14 in Salt Lake City, Utah. As an industry leader, StageBio is committed to the advancement of toxicological knowledge in the broader scientific community.  For this upcoming event we will be delivering both an insightful presentation on ocular toxicology and a standout poster about Immunotoxicity. Please visit us at our booth #717 and interact with our dynamic team of industry experts, ready to engage in discussions on how we can best assist you.

StageBio’s SOT informative sessions and presentations include the following: 

“Through the Lens: Translational Insights in Ocular Toxicology” on Wednesday, March 13, 2024 from 11:00am–12:20pm. Dr. Stephanie Shrader, DVM, Ph.D., DACVP, Director, General Toxicologic Pathology, Ocular Service Lead of StageBio, will be presenting on “Necropsy, Histology, and Pathology Considerations in Ocular Toxicity Studies,” and the session will be co-chaired by Dr. Tracey Papenfuss, DVM, M.S., Ph.D. (Immunology), DACVP, FIATP, Senior Pathologist/Principal Investigator, Immune Service Lead, of StageBio. During this session, attendees will provide an overview by veterinary specialists on the comparative and translational considerations in ocular toxicology. Attendees will hear the fundamentals of ocular biology, ophthalmologic examination techniques, pathology-specific considerations, and regulatory (including adversity) considerations.

StageBio and Noble Life Sciences have partnered to present a poster at the Immunotoxicity II Poster Session at the ToxExpo‚ Exhibit Hall C, Salt Palace Convention Center on March 12 from 11:45am - 1:45pm. The poster looks at study considerations in determining efficacy and immunosafety profiles in a nonclinical mouse model system. The poster is entitled, “Biodistribution, kinetics, phenotyping, and imaging data endpoints determine efficacy and immunosafety profiles of CAR T-cells and xenogeneic tumor cells in a mouse model of Acute Lymphoblastic Leukemia (ALL) using NSG mice,” and is co-authored by Dr. Tracey Papenfuss, BS, DVM, M.S., Ph.D. (Immunology), DACVP, FIATP, Senior Pathologist/Principal Investigator, Immune Service Lead, of StageBio and Noble Life Sciences experts Dr. Arundhati Ghosh, Ph.D., MSc, Ms. Kali Cook, M.S, Dr. Pang-Kuo Lo, Ph.D. MSc, Dr. Yongping Chen, M.D., Ph.D., Dr. Janet Olugbodi, MSc., Ph.D. and Dr. Todd Parsley, Ph.D.

The SOT Expo event supports organizations involved in the toxicology community. The StageBio team looks forward to seeing our clients and partners during this 5 day event, with over 70 scientific sessions to attend, poster sessions, networking time and the ToxExpo.  Attendees can expect to connect with research organizations, government agencies, laboratory supplies, drug developers, and academic institutions.   

StageBio’s cutting edge histopathology techniques and consulting services are here to support your studies through every step of the process. We invite you to stop by our booth #717 and we can hear your upcoming 2024 research goals, and how StageBio can help you achieve them.

About StageBio

StageBio is a leading provider of GLP-compliant necropsy, histology, pathology, and specimen archiving and biorepository services for the biopharmaceutical, medical device, academic, and contract research industries. The company operates four GLP laboratories as well as three GLP specimen archiving facilities throughout the US and Europe. StageBio continues to make investments in facility and technology infrastructure to meet the growing demand for high-quality histopathology services globally. StageBio has a team of 30+ board-certified veterinary pathologists and more than 100 laboratory technicians on staff supporting our unified commitment to quality, scientific integrity, and client satisfaction. Learn more about StageBio here.

Back to Index

Learn more about StageBio’s COVID-19 response